Ketamine Lead Gen expanded offerings to include semaglutide and NAD

Ketamine Lead Gen is a leading provider of comprehensive lead generation and digital marketing services for clinics and practitioners in the mental health and wellness industry. Her specialized expertise in ketamine therapy, TMS, semaglutide and NAD infusion therapies helps businesses effectively reach their target audience and convert leads into valuable patients.

Semaglutide

Known by the brand names Ozempic and Wegovy, semaglutide is an FDA-approved weight loss medication that has also been shown to help patients with depression. It works by releasing the glucagon-like peptide 1 (GLP-1) hormone when we eat, which stimulates insulin release, suppresses ghrelin, and slows down appetite to promote feelings of fullness.

Semaglutide can be injected once a week, directly into the muscle tissue of the abdomen or thighs. The injection site is small and easy to target, and most patients find that they feel no discomfort or pain after the first few doses.

Ketamine has been used for five decades in human and veterinary medicine, mainly as an anesthetic for surgery. More recently, it has been able to induce a “reboot” in certain depressed patients by triggering the production of glutamate in the brain. This allows new pathways to open up and repair damage caused by past traumas or chemical imbalances.

PCN-101

PanTher’s lead candidate, PTM-101, is a minimally invasive implant designed to consistently deliver a known drug directly to a cancer tumor site. It is currently in phase I evaluations for patients with non-metastatic disease. The company will use the grant to advance PTM-101 and its Sagittari platform for innovative localized cancer treatments.

Freedom Biosciences is backed by industry heavyweights including John Krystal, chair of the department of psychiatry at Yale University, and Dina Burkitbayeva, one of the early investors in therapeutic mRNA companies. The company’s ketamine program, called FREE001, has shown that a combination approach provides more durable antidepressant benefits than ketamine monotherapy in preclinical studies.